Paul Matteis
Stock Analyst at Stifel Nicolaus
(4.78)
# 582
Out of 4,974 analysts
747
Total ratings
50.6%
Success rate
15.3%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RAPP Rapport Therapeutics | Reiterated: Buy | $56 | $42.62 | +31.39% | 12 | Sep 16, 2026 | |
| CTNM Contineum Therapeutics | Reiterated: Buy | $28 | $13.82 | +102.60% | 12 | Sep 15, 2026 | |
| DFTX Definium Therapeutics | Reiterated: Buy | $60 → $67 | $36.82 | +81.97% | 8 | Sep 15, 2026 | |
| SION Sionna Therapeutics | Reiterated: Hold | $7 | $6.88 | +1.74% | 6 | Sep 15, 2026 | |
| KRSA Korsana Biosciences | Initiated Coverage: Buy | $43 | $32.08 | +34.04% | 1 | Sep 14, 2026 | |
| DYN Dyne Therapeutics | Reiterated: Buy | $37 | $17.90 | +106.70% | 28 | Sep 8, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | $318 | $238.27 | +33.46% | 50 | Aug 31, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Hold | $70 | $64.45 | +8.61% | 47 | Aug 31, 2026 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $21 | $13.81 | +52.06% | 8 | Aug 13, 2026 | |
| LBRX LB Pharmaceuticals | Reiterated: Buy | $40 → $53 | $43.04 | +23.14% | 4 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $46 | $33.69 | +36.54% | 25 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $2.89 | +315.22% | 18 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $71 | $43.10 | +64.73% | 27 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $22.96 | +30.66% | 3 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $86 | $56.28 | +52.81% | 29 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $500 | $514.63 | -2.84% | 43 | Aug 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $41 | $20.38 | +101.18% | 29 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $32 → $38 | $27.55 | +37.93% | 11 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $25 | $26.76 | -6.58% | 51 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $214 → $242 | $216.17 | +11.95% | 52 | Aug 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $86 → $68 | $47.25 | +43.92% | 33 | Aug 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $188 → $215 | $150.02 | +43.31% | 55 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $63 | $46.03 | +36.87% | 59 | Jul 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 | $4.13 | +311.62% | 9 | Jul 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 | $0.2361 | +323.55% | 8 | Jul 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $133 | $96.77 | +37.44% | 12 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 → $36 | $12.08 | +198.01% | 4 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $10.37 | +141.08% | 3 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 | $0.8313 | +260.88% | 10 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $33 | $30.25 | +9.09% | 10 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.04 | - | 12 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $2.89 | +246.02% | 9 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $7.24 | n/a | 11 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $13.91 | n/a | 11 | Jun 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 | $4.46 | n/a | 13 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $11 → $20 | $67.30 | n/a | 4 | Feb 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $0.0001 | n/a | 1 | Aug 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 → $20 | $0.0001 | n/a | 4 | Mar 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.68 | n/a | 1 | Nov 23, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.35 | n/a | 4 | Jun 20, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 | $17.04 | n/a | 5 | Jun 20, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $0.0003 | n/a | 3 | May 19, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $14 → $7 | $0.7554 | n/a | 2 | May 6, 2016 |
Rapport Therapeutics
Sep 16, 2026
Reiterated: Buy
Price Target: $56
Current: $42.62
Upside: +31.39%
Contineum Therapeutics
Sep 15, 2026
Reiterated: Buy
Price Target: $28
Current: $13.82
Upside: +102.60%
Definium Therapeutics
Sep 15, 2026
Reiterated: Buy
Price Target: $60 → $67
Current: $36.82
Upside: +81.97%
Sionna Therapeutics
Sep 15, 2026
Reiterated: Hold
Price Target: $7
Current: $6.88
Upside: +1.74%
Korsana Biosciences
Sep 14, 2026
Initiated Coverage: Buy
Price Target: $43
Current: $32.08
Upside: +34.04%
Dyne Therapeutics
Sep 8, 2026
Reiterated: Buy
Price Target: $37
Current: $17.90
Upside: +106.70%
Alnylam Pharmaceuticals
Aug 31, 2026
Reiterated: Buy
Price Target: $318
Current: $238.27
Upside: +33.46%
BioMarin Pharmaceutical
Aug 31, 2026
Reiterated: Hold
Price Target: $70
Current: $64.45
Upside: +8.61%
COMPASS Pathways
Aug 13, 2026
Reiterated: Buy
Price Target: $21
Current: $13.81
Upside: +52.06%
LB Pharmaceuticals
Aug 13, 2026
Reiterated: Buy
Price Target: $40 → $53
Current: $43.04
Upside: +23.14%
Aug 13, 2026
Reiterated: Buy
Price Target: $46
Current: $33.69
Upside: +36.54%
Aug 13, 2026
Reiterated: Buy
Price Target: $12
Current: $2.89
Upside: +315.22%
Aug 13, 2026
Reiterated: Buy
Price Target: $71
Current: $43.10
Upside: +64.73%
Aug 13, 2026
Reiterated: Buy
Price Target: $30
Current: $22.96
Upside: +30.66%
Aug 13, 2026
Reiterated: Buy
Price Target: $86
Current: $56.28
Upside: +52.81%
Aug 9, 2026
Reiterated: Hold
Price Target: $500
Current: $514.63
Upside: -2.84%
Aug 7, 2026
Reiterated: Buy
Price Target: $41
Current: $20.38
Upside: +101.18%
Aug 6, 2026
Reiterated: Buy
Price Target: $32 → $38
Current: $27.55
Upside: +37.93%
Aug 5, 2026
Reiterated: Hold
Price Target: $25
Current: $26.76
Upside: -6.58%
Aug 2, 2026
Reiterated: Buy
Price Target: $214 → $242
Current: $216.17
Upside: +11.95%
Aug 2, 2026
Reiterated: Hold
Price Target: $86 → $68
Current: $47.25
Upside: +43.92%
Jul 31, 2026
Reiterated: Buy
Price Target: $188 → $215
Current: $150.02
Upside: +43.31%
Jul 25, 2026
Reiterated: Buy
Price Target: $63
Current: $46.03
Upside: +36.87%
Jul 6, 2026
Reiterated: Buy
Price Target: $17
Current: $4.13
Upside: +311.62%
Jul 6, 2026
Reiterated: Hold
Price Target: $1
Current: $0.2361
Upside: +323.55%
Jun 15, 2026
Reiterated: Buy
Price Target: $133
Current: $96.77
Upside: +37.44%
Jun 2, 2026
Reiterated: Buy
Price Target: $28 → $36
Current: $12.08
Upside: +198.01%
May 28, 2026
Reiterated: Buy
Price Target: $25
Current: $10.37
Upside: +141.08%
May 12, 2026
Reiterated: Hold
Price Target: $3
Current: $0.8313
Upside: +260.88%
Apr 2, 2026
Reiterated: Buy
Price Target: $33
Current: $30.25
Upside: +9.09%
Dec 22, 2025
Rated: Hold
Price Target: n/a
Current: $2.04
Upside: -
Dec 16, 2025
Reiterated: Buy
Price Target: $10
Current: $2.89
Upside: +246.02%
Sep 19, 2024
Rated: Hold
Price Target: n/a
Current: $7.24
Upside: n/a
Jun 3, 2023
Reiterated: Buy
Price Target: $5
Current: $13.91
Upside: n/a
May 12, 2022
Reiterated: Hold
Price Target: $3
Current: $4.46
Upside: n/a
Feb 28, 2022
Downgraded: Hold
Price Target: $11 → $20
Current: $67.30
Upside: n/a
Aug 16, 2017
Initiated Coverage: Buy
Price Target: $18
Current: $0.0001
Upside: n/a
Mar 10, 2017
Reiterated: Buy
Price Target: $14 → $20
Current: $0.0001
Upside: n/a
Nov 23, 2016
Reiterated: Buy
Price Target: n/a
Current: $2.68
Upside: n/a
Jun 20, 2016
Reiterated: Buy
Price Target: n/a
Current: $2.35
Upside: n/a
Jun 20, 2016
Reiterated: Buy
Price Target: $29
Current: $17.04
Upside: n/a
May 19, 2016
Reiterated: Buy
Price Target: $11
Current: $0.0003
Upside: n/a
May 6, 2016
Reiterated: Hold
Price Target: $14 → $7
Current: $0.7554
Upside: n/a